Treatment Patterns and Medication Adherence Among Patients Diagnosed with Multiple Myeloma and Treated with Panobinostat

References

• American Cancer Society . Cancer Facts and Figures 2016. American Cancer Society, GA, USA (2016). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html
   Google Scholar
• Kleber M , IhorstG, TerhorstMet al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J.1(9), e35 (2011).
   PubMedGoogle Scholar
• Palumbo A , AndersonKC. Multiple myeloma. N. Engl. J. Med.364(11), 1046–1060 (2011).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV , DimopoulosMA, PalumboAet al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol.15(12), e538–e548 (2014).
   PubMed Web of Science ®Google Scholar
• Anderson KC , AlsinaM, AtanackovicDet al. NCCN Guidelines Insights: multiple myeloma, version 3.2016. J. Natl Compr. Canc. Netw.14(4), 389–400 (2016).
   PubMed Web of Science ®Google Scholar
• SEER Cancer Stat Facts: myeloma . National Cancer Institute, Bethesda, MD, USA. https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Bailey H , StenehjemDD, SharmaS. Panobinostat for the treatment of multiple myeloma: the evidence to date. J. Blood Med.6, 269–276 (2015).
   PubMedGoogle Scholar
• Kumar SK , DispenzieriA, LacyMQet al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia28(5), 1122–1128 (2014).
   PubMed Web of Science ®Google Scholar
• PDQ® Adult Treatment Editorial Board . PDQ plasma cell neoplasms (including multiple myeloma) treatment. National Cancer Institute, Bethesda, MD, USA Updated 3 February2017. www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq
   Google Scholar
• Richardson P , MitsiadesC, SchlossmanRet al. The treatment of relapsed and refractory multiple myeloma. Hematol. Am. Soc. Hematol. Educ. Program1, 317–323 (2007).
   Google Scholar
• San-Miguel JF , HungriaVTM, YoonS-Set al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, doubleblind Phase III trial. Lancet Oncol.15(11), 1195–1206 (2014).
   PubMed Web of Science ®Google Scholar
• Richardson PG , HungriaVT, YoonSSet al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood127(6), 713–721 (2016).
   PubMed Web of Science ®Google Scholar
• FARYDAK® (panobinostat) capsules, for oral use . US prescribing information, revised June 2016. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2016). www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/farydak.pdf
   Google Scholar
• Greig SL . Panobinostat: a review in relapsed or refractory multiple myeloma. Target Oncol.11(1), 107–114 (2016).
   PubMed Web of Science ®Google Scholar
• San-Miguel JF , HungriaVTM, YoonS-Set al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, Phase III trial. Lancet Haematol.3(11), e506–e515 (2016).
   PubMed Web of Science ®Google Scholar
• Richardson PG , SchlossmanRL, AlsinaMet al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood122(14), 2331–2337 (2013).
   PubMed Web of Science ®Google Scholar
• Hansen VL , ColemanM, ElkinsSet al. An expanded treatment protocol of panobinostat plus bortezomib and dexamethasone in patients with previously treated myeloma. Clin. Lymphoma Myeloma Leuk.126, 3027 (2018).
   Google Scholar
• Redic KA , HoughSM, PriceEM. Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco. Targets Ther.9, 2783–2793 (2016).
   PubMed Web of Science ®Google Scholar
• Chari A , ChoHJ, LengSet al. Phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood126(23), 4226 (2015).
   Google Scholar
• Peterson AM , NauDP, CramerJA, BennerJ, Gwadry-SridharF, NicholM. A checklist for medication compliance and persistence studies using retrospective databases. Value Health10(1), 3–12 (2008).
   Web of Science ®Google Scholar
• Deyo RA , CherkinDC, CiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol.45(6), 613–619 (1992).
   PubMed Web of Science ®Google Scholar
• SEER-Medicare: Calculation of Comorbidity Weights. National Cancer Institute, Bethesda, MD, USA. https://healthcaredelivery.cancer.gov/seermedicare/considerations/calculation.html
   Google Scholar
• Maly JJ , ChristianBA, ZhuXet al. A Phase I/II trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Clin. Lymphoma Myeloma Leuk.17(6), 347–353 (2017).
   PubMed Web of Science ®Google Scholar
• Liu L , ZhaoN, XuW, ShengZ, WangL. Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with relapsed/refractory multiple myeloma. J. Hematol. Oncol.9(1), 54 (2016).
   PubMedGoogle Scholar
• Chari A , ChoHJ, DhadwalAet al. A Phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv.1(19), 1575–1583 (2017).
   PubMed Web of Science ®Google Scholar
• Song X , CongZ, WilsonK. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr. Med. Res. Opin.32(1), 95–103 (2016).
   PubMed Web of Science ®Google Scholar
• Fonseca R , AbouzaidS, BonafedeMet al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia31(9), 1915–1921 (2017).
   PubMed Web of Science ®Google Scholar